We have shown recently that a retrovirus vector expressing a natural mutant form of the PML-RARa protein characteristic of human acute promyelocytic leukaemia can transform early chicken hematopoietic progenitors (Altabef et al., 1996) . Neither truncated PML nor truncated RARa alone could induce transformation which suggest that the two domains should cooperate for the oncogenicity of the fusion product. To further investigate the mechanisms of this co-operation, we have tested whether a truncated RARa could cooperate with the v-erbB oncogene. This oncogene has previously been shown to co-operate with the rearranged thyroid hormone receptor, v-erbA, to transform erythrocytic progenitors. We show that v-erbB and a truncated RARa co-operate when expressed simultaneously as independent products to transform very early chicken haematopoietic cells close to pluripotent stage. In addition, we show that v-erbB alters transcriptional abilities of RARa by both enhancing its eects on RARE and reducing those on AP-1. Therefore, RARa is able to co-operate with dierent kinds of proteins to induce transformation of early haematopoietic cells. This strongly suggests that RARa are involved in the dierentiation commitment of early haematopoietic progenitors during the normal process of haematopoietic dierentiation. These data bring new insights in the mechanisms of oncogenic transformation by rearranged RARa.
Introduction
Retinoids play major roles in embryogenesis, homeostasis, cell growth and dierentiation (Chambon, 1993; Gudas, 1994) . Their action is mediated by several nuclear receptors which behave as ligandinducible transcription activators (Kastner et al., 1995; Mangelsdorf et al., 1994) . They regulate target gene transcription through binding to cognate response elements (RARE). Three subtypes of Retinoic Acid Receptors (RAR) have been identi®ed: a, b and g which bind both all-trans and 9-cis Retinoic Acid (RA). Three subtypes of Retinoid-X Receptors (RXR), a, b and g respectively, were also identi®ed which only bind 9-cis RA (Allenby et al., 1994; Heyman et al., 1992; Levin et al., 1992) . Multiple isoforms of each receptor subtype have been described which result either from alternative promoter or alternative splicing usages. RARs and RXRs belong to the hormone nuclear receptors superfamily containing also steroid, thyroid and vitamin D3 receptors (Mangelsdorf et al., 1995a; Tsai and O'Malley, 1994a) . All these receptors consist of several structurally and functionally distincts motifs essentially organized around the DNA binding domain in the amino-terminal part, and the ligand binding domain in the carboxy-terminal region.
Several observations suggest that RARs are involved in regulating haematopoiesis: (i) terminal dierentiation of neutrophilic cells is induced by RA and mediated by RAR (Collins et al., 1990; Tsai et al., 1992) ; (ii) infection of fresh mouse bone marrow cells with a retrovirus expressing a dominant-negative RAR generates immortalized lympho-haematopoietic progenitors, which can undergo lymphoid, myeloid and erythroid dierentiation (Tsai et al., 1994b) ; (iii) the rearranged form of RARa, PML-RARa, transforms early progenitors in chicken (Altabef et al., 1996) . On the other hand, RAR have been involved in several types of human cancer. A rearranged RARb has been found in a hepatocellular carcinoma (HCC) consecutive to Hepatitis B Virus infection (HBV) (Dejean et al., 1986) . We have demonstrated the oncogenicity of this rearranged HBV-RARb (Garcia et al., 1993) . Furthermore, a truncated form of RARa is involved in two speci®c translocations: t(15;17) and t(11;17), detected exclusively in patient suering from Acute Promyelocytic Leukaemia (APL) (Alcalay et al., 1991; Borrow et al., 1990; Chen et al., 1993; de TheÂ et al., 1990) . These translocations result in the fusion of the N-terminal truncated RARa with a C-terminal truncated form of PML (Promyelocytic Myeloid Leukaemia) or PLZF (Promyelocytic Leukaemia Zinc Finger) respectively.
The v-erbA oncogene carried by Avian Erythroblastosis Virus (AEV) is a rearranged form of the nuclear receptor for thyroid hormone T3. In AEV, it cooperates with the v-erbB oncogene to induce erythroleukaemia in chicken and to transform erythrocytic progenitors in vitro. The v-erbB oncogene encodes a rearranged form of the tyrosine kinase membrane receptor for both Epidermal Growth Factor (EGF) and Transforming Growth Factor a (TGF-a). It induces mitogenic activation and growth factor independence to leukaemic cells (Frykberg et al., 1983; Gandrillon et al., 1989) . v-erbB alone induces an erythroblastosis without blocking cell dierentiation (Frykberg et al., 1983; Garcia and Samarut, 1990 ). Since we showed earlier that a N-terminal truncated RARa is unable to transform haematopoietic cells, we have tested whether its oncogenicity could be restored by co-operation with the v-erbB oncogene.
We show that co-operation between a N-terminal truncated form of RARa and the v-erbB oncoprotein induces acute leukaemias in chicken and transforms very early haematopoietic progenitors in vitro. These experiments show another example of the retinoic acid receptors' oncogenic potential and strongly suggest their involvement at the dierentiation commitment of very early haematopoietic precursors.
Results

Structure of retrovirus vectors
We have previously described the avian retrovirus DRaN which encodes a gag-RARa fusion product (Altabef et al., 1996) . This virus was based on the AEV genome in which RARa was inserted in place of the v-erbA oncogene and where the v-erbB oncogene was deleted. In this construct, RARa was truncated of the A/B region ( Figure 1a) , and then corresponds to the domain fused to PML in the human PML-RARa natural fusion product (Alcalay et al., 1991; Borrow et al., 1990; de TheÂ et al., 1990) . The DRaN virus also contains the Neo R gene which allows selection of infected cells with G418 ( Figure 1b) . To analyse the co-operation of RARa with v-erbB, the v-erbB coding sequence from AEV was conserved. In this virus called DRaBN (Figure 1b) , the verbB product is expressed from subgenomic viral RNA. As control, we used the virus TXN, a retrovirus carrying only Neo R gene (Benchaibi et al., 1989) and the virus AEV-Pst124 encoding only the v-erbB oncoprotein (Gandrillon et al., 1987) .
The virus DRaBN transforms chicken bone marrow cells in vitro
To analyse the oncogenic properties of the retrovirus vectors on haematopoietic progenitors, bone marrow cells (BMC) from 17 ± 19 day-old chicken embryos were infected in vitro with similar doses of the respective viruses and then seeded in methylcellulose cultures containing G418.
As previously observed, in cultures infected either by TXN or DRaN, only few red colonies arose from the infected normal erythrocytic progenitors BFU-Es which were not aected in their dierentiation (data not shown; Altabef et al., 1996) . In culture infected by AEV-Pst124, typical pink colonies appeared containing erythroid cells mostly at CFU-E stage together with more dierential erythroblasts ( Figure  2a , Gandrillon et al., 1989) . In contrast, in the DRaBN-infected cultures, white spherical colonies (Figure 2b ) appeared after 7 days at a frequency of approximately 80 colonies per 10 6 seeded cells. These colonies were similar in shape and size to the transformed colonies observed after infection of chicken BMC with PRaN, a recombinant retrovirus vector expressing a natural mutant form of PMLRARa (Altabef et al., 1996) or with AEV or E26 (Moscovici et al., 1983; Samarut and Gazzolo, 1982) . When picked and seeded in liquid culture, the cells composing those colonies exhibited an immature blastic phenotype characterized by a very diuse chromatin and a narrow rim of cytoplasm ( Figure  2c ). These cells grew with a 18 ± 24 h-doubling time (see Figure 5b ) and could be passed for nearly 30 generations after which they became senescent. They could also grow in low-serum medium (data not shown). On the contrary, the AEV-Pst124 infected cells quickly dierentiated into erythrocytes, under these culture conditions, and stopped growing. Protein analyses revealed the expected 78 kDa gagDRARa product in DRaBN-transformed cells ( Figure  3 , DRaBN BMC). Taken together, these data show that the cells infected by DRaBN are transformed since they exhibit a homogenous immature phenotype, a strong proliferative ability and a low growth factor requirement.
Characterization of the haematopoietic cells transformed by DRaBN
From their morphology, the DRaBN-transformed cells could not be classi®ed in a precise haematopoietic lineage. To determine more precisely the nature of these cells, we analysed their expression of the speci®c membrane antigens described by McNagny et al. (1992) . The MEP 17 antigen is expressed at high levels on E26 transformed multipotent cells, T and B lymphocytes and thrombocytes, and at much lower levels on late erythrocytic, myelomonocytic and eosinophilic cells . The MEP 21 and MEP 26 antigens are present on transformed progenitor cells able to dierentiate into erythrocytes, myeloblasts, thrombocytes and eosinophilic cells but their expression is extinguished during the differentiation, except on the mature thrombocytes. Moreover, MEP 21 and MEP 26 are not expressed on lymphoid cells . These antigens are therefore characteristic of multipotent precursors. The MYL 51/2 antigen is speci®c of normal and transformed myelomonocytic cells and is absent from erythroid and lymphoid cells McNagny et al., 1992) . The expression of all these antigens was investigated on the DRaBN-transformed cells comparatively to erythrocytic cells transformed by The data are presented in Figure 4 . As expected, E26 multipotent HD 57 E cells were positive only for the MEP 17, MEP 21 and MEP 26 antigens, myeloid E26-transformed cells exhibited only the MEP 17 and MYL 51/2 antigens, and erythroid AEV-transformed cells were negative for all tested antigens. The DRaBN-transformed cells did not exhibit the MEP 21 and MYL 51/2 antigens whereas they expressed the MEP 17 antigen at an intermediate level and the MEP 26 antigen at the same level as multipotent E-26 cells. Therefore, the DRaBN-transformed cells expressed antigens characteristic of multipotent precursors. Their pattern remind us of the previously described pattern for chicken cells transformed by PRaN, a retrovirus carrying the cDNA of PML-RARa (Altabef et al., 1996) .
Since the E26 multipotent cells can be induced to dierentiate into myeloid lineage by treatment with TPA , we applied a similar treatment to the DRaBN-transformed cells but we did not see any evidence of cell-dierentiation, even in the presence of RA 10 76 M (data not shown). Consistent with this result, the presence of RA did not modify the transformation frequency of the cells in semi-solid medium (Figure 5a ). However, in this condition the colonies showed a more dispersed shape and seemed to contain slightly fewer cells (data not shown). In liquid cultures, in the presence of RA, growth was slightly delayed compared to cultures without RA, but after a 2 day-latency, the growth rate became similar to that of non-treated cells. Moreover, there was no induction of dierentiation of the cells.
These data taken all together suggest that the cells transformed by DRaBN are resistant to induction of dierentiation and growth inhibition by RA and are very immature haemopoietic progenitors with a phenotype close to multipotent cells.
The DRaBN retrovirus induces an acute leukaemia in vivo
To test the leukaemogenic potentialities of DRaBN in vivo, the virus was injected intravenously into 10 dayold chicken embryos. As controls, embryos were injected with the DRaN virus. As shown in Table 1 , nearly 50% of the embryos infected with DRaBN developed a leukaemia within 2 weeks after hatching. In contrast, no sign of leukaemia was ever seen in the animals infected either with DRaN within 6 weeks after hatching (Table 1) , or with TXN within 8 weeks after hatching (data not shown; Gandrillon et al., 1989) . Control chickens infected with the AEV-Pst124 virus carrying v-erbB only developed an erythroblastosis with immature erythrocytic cells at all differentiation stages (not shown; Garcia and Samarut, 1990) .
Leukaemic cells in the blood of the DRaBN-infected chickens were very similar to those developed in vitro from infection of bone marrow with the virus (Figure  2d ). Bone marrow cells from leukaemic chicks could be grown in culture similar to cells obtained from in vitro infection. They expressed the expected DRARa-78 kDa protein (Figure 3, DRaBN leukaemic BMC) . Dissection of the leukaemic animals did not reveal any other aected organs.
Therefore, these data show that the DRARa gene induces an acute leukaemia in vivo in co-operation with v-erbB.
v-erbB alters transcriptional activity of DRARa
RARa, as all other RARs, can control gene transcription either through direct binding to target response elements or through inactivation of the AP-1 transcription factor (Desbois et al., 1991; Nicholson et al., 1990; SchuÈ le et al., 1991; Yang-Yen et al., 1991) . We have previously shown that the truncated DRARa has retained these two properties (Altabef et al., 1996) . We then investigated whether the co-operative eect of v-erbB in transformation might result from altering the transcriptional activity of DRARa. For that purpose, we performed transient expression assays, in HeLa cells, in the presence or in the absence of RA by transfecting expression vectors of either RARa or DRARa together with v-erbB. These data are presented in Figure 6a .
As previously reported, the RARa product could transactivate a reporter plasmid containing a Chloramphenicol Acetyl Transferase (CAT) gene driven by a SV 40 promoter fused to a single bRARE (pSVbRE) in the presence of RA 10 76 M (Sucov et al., 1990) . Truncation of the N-terminus part slightly increased the transactivation activity of DRARa compared to RARa. In both cases, addition of the increasing amounts of expression vector of v-erbB enhanced the transcriptional activity of the receptors. Curiously, for the used amounts of v-erbB, endogenous response to RA was repressed (Figure 6a ). The dierence of eects of v-erbB between basal response to RA and the response to exogenously expressed RARa or DRARa is not explained. One possibility could be that the endogenous response to RA is mediated by RAR subtypes dierent from RARa, either RARb or RARg.
To investigate the eects of v-erbB on the inactivation of AP-1 by RARa and DRARa, transfection experiments were performed with the interstitial collagenase promoter as reporter (Desbois et al., 1991) . AP-1 activity in HeLa cells was raised by TPAtreatment (Desbois et al., 1991) . As previously described, ligand-activated RARa and DRARa strongly repressed the TPA-induced collagenase promoter activity (Figure 6b ). DRARa was even more ecient than entire RARa. In these conditions, increasing amounts of v-erbB expression vector strongly reduced the inhibition of AP-1 by DRARa and had a slighter reducing eect on the inhibition mediated by RARa (Figure 6b and c) . We also analysed the behaviour of v-erbB alone in the presence of TPA. We showed that increasing amounts of v-erbB greatly enhanced the basal activity of AP-1 (Figure 6b) . Surprisingly, in the presence of RA, this enhancement was highly reduced. Therefore, we assumed that in the presence of RA, v-erbB interferred with endogenous RAR in the same way as it did with the transfected RARa. In contrast, in the absence of TPA, v-erbB alone did not generate any signi®cant AP-1 activity even when transfected at high concentrations ( Figure  6b ).
These data show that v-erbB alters the transcriptional activity of RARa and DRARa, both on the 
Discussion
Direct involvement of nuclear receptors of the RAR family in oncogenesis was ®rst illustrated by the v-erbA oncogene, one oncogene of AEV which encodes a rearranged form of the c-erbAa receptor for the thyroid hormone T3 (Gandrillon et al., 1995) . This oncogene co-operates with the v-erbB product for the leukaemogenesis. Whereas v-erbA is supposed to be responsible for the blockade of the leukaemic cells, it has been shown that v-erbB induces mitogenic activation and growth factor independence to the transformed cells (Frykberg et al., 1983; Gandrillon et al., 1989; Pain et al., 1991) . On the other hand, in a human hepatocarcinoma consecutive to HBV infection, a rearranged form of the RARb has been identi®ed (de TheÂ et al., 1987) . This rearranged receptor is fused at its amino-terminus to the pre-S1 peptide of HBV. Expression of this rearranged HBV-RARb into chicken embryos using a retrovirus vector induced hepatic neoplasias and transformation of erythrocytic progenitor cells (Garcia et al., 1993) . In human acute promyelocytic leukaemia resulting from a t(15;17) chromosome translocation, a rearranged form of RARa is expressed as a fusion product PML-RARa. We have recently shown that an avian retrovirus, PRaN, expressing a naturally mutated form of PMLRARa fusion protein transforms very early chicken haematopoietic progenitor cells in vitro and induces acute leukaemias (Altabef et al., 1996) . We have also We show here that the v-erbB oncogene co-operates with DRARa in inducing oncogenic transformation and blocking dierentiation of early haematopoietic progenitors in chicken. These data are strengthened by analyses of biochemical co-operation between v-erbB and DRARa. Cotransfection of v-erbB enhanced transcriptional activity of DRARa on a bRARE and strongly reduced its inhibitory activity on AP-1 in the presence of RA. Very interestingly, similar changes in DRARa properties were observed when it is fused to PML (Altabef et al., 1996; Doucas et al., 1993; Kakizuka et al., 1991) . In erythroleukaemic transformation by AEV, v-erbB has been shown to provide mitogenic activity and growth factor independence to erythrocytic cells blocked by v-erbA. Therefore, in DRaBN-transformed cells, we may speculate that v-erbB also alters the growth properties of leukaemic cells. This assumption is supported by the strong reducing activity of v-erbB on the AP-1 inhibition of RAR. It is surprising that haematopoietic cells transformed by coexpression of DRAR and v-erbB are resistant to induction of dierentiation by retinoic acid. We have sequenced the DRAR cDNA in the provirus integrated in hematopoietic cells transformed in vitro and were unable to ®nd any rearrangement in the ligand binding domain of the DRAR product (data not shown). We might then assume that either the truncation of RAR at its N-terminus or its cooperation with the v-erbB product could indirectly alter its response to retinoic acid. The biochemical mechanisms through which v-erbB co-operates with DRARa are still unknown. Either v-erbB indirectly changes the phosphorylation pattern of DRARa, or it alters some pathways which interfere with it in the transcriptional control of target genes. Abrogation of DRARa-inactivation of AP-1 certainly plays an important role in leukaemia process. Indeed, in AEV leukaemic cells, the ability of v-erbA to abrogate RAR-or T3R-mediated AP-1 inhibition has been shown to be essential for the oncogenic transformation (Desbois et al., 1991) . On the other hand, there are several mechanisms by which RARa could act. It is now well-known that RARs preferentially function through dimerization with RXR (Mangelsdorf and Evans, 1995b) . Sequestration of RXRs by DRARa may prevent the formation of functional RAR-RXR heterodimers or heterodimers between RXR and other nuclear receptors and thereby modify the function of normal RARa or related receptors. DRARa may also compete for interactions with other transcription or regulator factors that may be necessary for RAR-or related receptors-transduction pathways. Interestingly, the DRARa/v-erbB association remains oncogenic even in presence of RA. We may imagine that verbB product either alters response of DRARa to RA or inhibits the function of cofactors of ligandactivated DRARa.
It is interesting to see that dierent rearranged nuclear receptors transform haematopoietic cells at various dierentiation stages. v-erbA and HBV-RARb, both block the dierentiation within the erythrocytic lineage at the level of early CFU-E (Garcia et al., 1993; Samarut and Gazzolo, 1982) . In contrast, rearranged RARa blocks dierentiation close to the pluripotent stem cells stage in chicken (present work and Altabef et al., 1996) and in mouse (Tsai et al., 1994b) . It has been shown that v-erbA, RARs and PML-RARa are able to form stable complexes with RXR suggesting that sequestration of RXR may contribute to the leukaemic transformation process (Hermann et al., 1993; Mangelsdorf and Evans, 1995b; Perez et al., 1993) . Since v-erbA, RARb, RARa and PML-RARa transform dierent target cells, titration of RXR is unlikely to account solely for the oncogenic phenotype and rather, this suggests that the altered receptors should interfere with speci®c co-factors at the various dierentiation steps.
In conclusion, the present work shows that RARa is able to co-operate in trans with an altered membrane receptor for the oncogenic transformation of very early haematopoietic progenitors. It opens new ®elds to investigate the molecular mechanisms underlying oncogenic transformation by retinoic acid receptors and to investigate dierentiation commitment at the level of pluripotent progenitors.
Materials and methods
Viruses
All virus genomes were constructed from an AEV-based retroviral vector containing a Neo resistance gene, as previously described (Altabef et al., 1996) . The original pNX 13 RARa plasmid was kindly provided by P Chambon (Strasbourg, France). A KpnI cloning site was created in position 230 from the initial codon by directed mutagenesis (Muta-gene M 13 kit TM , Biorad, Richmond, California), and used to delete the 5' region of the RARa sequence corresponding to the 77 ®rst amino-acids of the protein. The truncated RARa fragment was cloned into the AEV backbone vector by XhoI-ApaI digestion, in phase with the viral residue Dgag. Obtained viruses were called DRaN or DRaBN depending on the presence or the absence of v-erbB oncogene respectively. For virus production, viruses were rescued as RAV-1 pseudotypes by transfection on Chicken Embryo Fibroblasts (CEF). They were titrated through their eciency in inducing resistance to G418 to infected CEF (Benchaibi et al., 1989) .
Infection of BMC
Fresh BMC from 17 ± 19 day-old chicken embryos were infected by cocultivation during 24 h with virus-producing G 418-selected CEF. They were then seeded in methylcellulose culture containing G 418 at 3 mg/ml as previously described (Gandrillon et al., 1989) . After 7 days, colonies were picked and seeded in liquid culture containing alpha MEM supplemented with 20% fetal bovine serum, 5% chicken serum and 5% bovine serum albumin (Sigma). Under low-serum conditions, the culture medium contained alpha MEM supplemented with 5% fetal bovine serum, 1% chicken serum and 2.5% bovine serum albumin.
Transfection of cells and CAT Assay
The CEF were transfected using the polybrene method described previously (Benchaibi et al., 1989) . The HeLa cells were transfected using a calcium phosphate procedure as described in Desbois et al. (1991) . RSV-b-Galactosidase (2 mg per dish) expression vector was used as an internal control to normalize for transfection eciencies. The amount of RSV-LTR was kept constant by complementing with an`empty' expression vector. CAT enzymatic activity was measured at room temperature by following the kinetics of chloramphenicol acetylation with [ 3 H]acetyl CoA as substrate (Desbois et al., 1991) or by using the CAT-ELISA kit (Boehringer Mannheim, Germany). One mg of reporter genes, p-517 Col-CAT (Angel et al., 1987) and pDSV bRE (Sucov et al., 1990) , were used per dish with 2 mg of expression vectors (pRSV-RARa and pRSVDRARa). For v-erbB-expression vector, the amount of pCBXN is indicated at the bottom of the histograms. Details of construction can be provided on request.
Flow cytometry analysis
Analysis of the membrane antigens was performed on freshly transformed BMC. The MEP 17, MEP 21, MEP 26 and MYL 51/2 cell surface antigens were detected after incubation for 30 min at room temperature with the respective antibodies kindly provided by T Graf (Heidelberg, Germany), diluted 1 : 200. Fluorescein isothiocyanate-labelled goat antibody (BioSys, France), diluted 1 : 100, was used as second antibody. Negative control was done with the second antibody alone. Antigen-positive cells were counted on a 10 000 cell sample using a Becton Dickinson FACStar Plus¯ow cytometer at 488 nm with a DF 530/30 ®lter (Ion Laser Technologies, USA). Data acquisitions and analyses were performed using a Lysis II software on a consort 340 computer (Hewlet Packard).
Protein analysis
Cells were harvested from cultures, washed in PBS, lysed by Dounce B and concentrated as described by RochetteEgly et al. (1991) . Ten mg of proteins were loaded onto a 7.5% SDS-polyacrylamide gel. After electrophoresis the samples were transferred to a nitrocellulose membrane and blocked in TBST 0.1% containing 5% of non-fat powder milk. Then they were incubated for 1 h at 378C with antiRARa rabbit polyclonal antibodies at 1 : 300 dilution in TBST. After washing in TBST, the anti-rabbit ECL horse radish peroxidase-linked whole donkey antibody (ECL Western blotting analysis protocol, Amersham, United Kingdom) was added for 40 min at room temperature at 1 : 3000 dilution. Detection reaction was done during 1 min and the membrane was exposed between 2 s and 15 min.
In vivo leukaemogenicity assay
One hundred to 200 ml of freshly harvested virus were injected into the chorioallantoic vein of 10 day-old embryos. After hatching, the animals were monitored twice weekly for leukaemia by preparing blood smears that were stained with Wright-Giemsa.
Staining of cells
Cultured cells spread onto slides by cytocentrifugation or blood cell smears were dried and ®xed in methanol before staining in a Wright-Giemsa solution 1/10 v/v (Sigma).
Cell lines and antibodies
The HD 57 E, HD 57 M, HD 4 cell lines as anti MEP 17, anti MEP 21, anti MEP 26 and anti MYL 51/2 antibodies were kindly provided by T Graf, Heidelberg, Germany. The anti-RARa antibody was kindly provided by P Chambon, Strasbourg, France.
